Ownership and insider activity for Legend Biotech Corporation (LEGN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Price
| Price | $21.63 (closing price, October 30, 2026) |
| Market Cap | $4.0B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-29 | Sanders Corazon (Corsee) D. | S-Sale | 27,370 | $259K |
| 2026-09-24 | Salovey Peter | A-Award | 28,330 | |
| 2026-09-24 | Heyman Tomas J. | A-Award | 20,986 | |
| 2026-09-24 | Mao Li | A-Award | 20,986 | |
| 2026-09-24 | Casey Patrick John | A-Award | 20,986 | |
| 2026-09-24 | Ji Darren Xiaohui | A-Award | 28,330 | |
| 2026-09-24 | Sanders Corazon (Corsee) D. | A-Award | 20,986 | |
| 2026-09-21 | Santos Carlos E | A-Award | 19,676 | |
| 2026-09-21 | Santos Carlos E | S-Sale | 5,430 | $50K |
| 2026-09-15 | Zhang Ingrid | A-Award | 1,131,860 |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.1M | $210.2M | $83.6M | $456.1M | $688.9M | $786.0M | $1.28B | $286.7M | $901.9M |
| Short-term Investments | 0 | $6.0M | $75.6M | $50.0M | $193.5M | $239.6M | $31.0M | $835.9M | $46.7M |
| Receivables | $228.7M | $108.6M | $35.8M | $82.6M | $58.5M | $44.5M | $157.1M | $124.9M | $250.3M |
| Inventory | $11,000 | $1.1M | $1.2M | $1.8M | $1.7M | $10.4M | $19.4M | $23.9M | $32.0M |
| Total Current Assets | $230.9M | $327.0M | $207.1M | $593.9M | $949.9M | $1.10B | $1.50B | $1.28B | $1.25B |
| Property, Plant & Equipment | $2.9M | $33.1M | $80.1M | $112.1M | $143.0M | $161.7M | $189.7M | $201.6M | $402.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $2,000 | $49,000 | $518,997 | $2.9M | $16.8M | $68.7M | $4.1M | $174.2M | $74.6M |
| Total Assets | $238.7M | $429.0M | $287.7M | $722.1M | $1.12B | $1.33B | $1.85B | $1.67B | $1.73B |
| Accounts Payable | $4.3M | $7.3M | $9.6M | $4.9M | $7.0M | $31.7M | $20.2M | $37.2M | $81.2M |
| Short-term Debt | 0 | 0 | $1.0M | $1.8M | 0 | 0 | 0 | 0 | $319.1M |
| Total Current Liabilities | $52.1M | $159.2M | $127.8M | $115.6M | $229.2M | $297.8M | $216.4M | $277.6M | $636.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | $120.5M | $260.9M | $281.3M | $301.2M | 0 |
| Total Liabilities | $226.5M | $420.4M | $410.6M | $122.3M | $353.5M | $586.7M | $597.2M | $629.6M | $731.6M |
| Retained Earnings | $8.5M | $5.7M | -$127.3M | -$116.5M | -$520.1M | -$966.5M | -$1.48B | -$1.66B | -$1.96B |
| Total Equity | $12.2M | $8.6M | -$122.9M | $597.8M | $765.9M | $744.3M | $1.25B | $1.04B | $1.00B |
| Total Debt | $269,000 | $4.3M | $6.1M | $3.7M | $123.0M | $284.5M | $328.7M | $350.6M | $413.7M |
| Net Debt | -$1.8M | -$211.9M | -$153.1M | -$502.4M | -$759.4M | -$741.1M | -$980.0M | -$772.1M | -$534.9M |
| Working Capital | $178.8M | $167.8M | $79.3M | $478.4M | $720.6M | $801.3M | $1.28B | $1.01B | $610.7M |
Financial Health
| Debt / Equity | 0.23 |
| Current Ratio | 3.04 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 2.46 |
Profitability
| Return on Equity | -8.70% |
| Return on Invested Capital | -3.71% |
| Return on Assets | -5.23% |
| Gross Margin | 56.58% |
| Operating Margin | -4.42% |
| Net Margin | -7.21% |
Related companies: VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of LEGN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks